Total Payments
$276,165
2024 Payments
$55,973
Companies
30
Transactions
671
Medicare Patients
303
Medicare Billing
$39,698
Payment Breakdown by Category
Other$175,075 (63.4%)
Research$49,817 (18.0%)
Consulting$30,545 (11.1%)
Food & Beverage$10,348 (3.7%)
Travel$10,280 (3.7%)
Education$99.54 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $172,325 | 67 | 62.4% |
| Unspecified | $49,817 | 40 | 18.0% |
| Consulting Fee | $30,545 | 7 | 11.1% |
| Food and Beverage | $10,348 | 477 | 3.7% |
| Travel and Lodging | $10,280 | 75 | 3.7% |
| Honoraria | $2,750 | 1 | 1.0% |
| Education | $99.54 | 4 | 0.0% |
Payments by Type
General
$226,348
631 transactions
Research
$49,817
40 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $95,281 | 147 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $62,010 | 112 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $47,964 | 30 | $0 (2018) |
| Axsome Therapeutics, Inc. | $21,502 | 15 | $0 (2024) |
| Brainsway USA INC | $15,893 | 6 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $8,465 | 20 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $7,649 | 22 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $6,595 | 7 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $5,119 | 36 | $0 (2024) |
| Lundbeck LLC | $897.11 | 53 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $55,973 | 124 | Supernus Pharmaceuticals, Inc. ($24,012) |
| 2023 | $91,805 | 168 | ABBVIE INC. ($52,659) |
| 2022 | $56,227 | 112 | ABBVIE INC. ($17,979) |
| 2021 | $7,325 | 73 | AbbVie Inc. ($5,980) |
| 2020 | $5,075 | 61 | Otsuka America Pharmaceutical, Inc. ($4,305) |
| 2019 | $10,820 | 56 | Janssen Pharmaceuticals, Inc ($8,319) |
| 2018 | $30,575 | 54 | ACADIA Pharmaceuticals Inc ($30,053) |
| 2017 | $18,365 | 23 | ACADIA Pharmaceuticals Inc ($17,911) |
All Payment Transactions
671 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: ADHD | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/26/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $27.16 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $27.61 | General |
| Category: PSYCHIATRY | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $33.91 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/06/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $27.24 | General |
| Category: PSYCHIATRY | ||||||
| 10/31/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.83 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | Tris Pharma Inc | Onyda XR (Drug) | Food and Beverage | In-kind items and services | $22.39 | General |
| Category: ADHD | ||||||
| 10/22/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: PSYCHIATRY | ||||||
| 10/15/2024 | Bausch Health US, LLC | APLENZIN (Drug), WELLBUTRIN | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Neurology | ||||||
| 10/09/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: ADHD | ||||||
| 10/01/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: NEUROSCIENCE | ||||||
| 09/18/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: ADHD | ||||||
| 09/11/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Neuroscience | ||||||
| 09/04/2024 | Noven Therapeutics, LLC | Xelstrym (Drug) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: ADHD | ||||||
| 08/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 08/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 08/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $266.45 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 08/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $204.24 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 08/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $204.24 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 08/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $130.16 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 08/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $130.16 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 08/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $27.76 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 08/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-042 | ACADIA Pharmaceuticals Inc | $40,974 | 11 |
| ACP-103-038 | ACADIA Pharmaceuticals Inc | $6,990 | 19 |
| A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,427 | 6 |
| Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $426.19 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 19 | 23 | $2,300 | $565.29 |
| 2022 | 3 | 67 | 234 | $24,540 | $9,164 |
| 2021 | 4 | 115 | 333 | $37,295 | $16,386 |
| 2020 | 3 | 102 | 278 | $33,520 | $13,583 |
Total Patients
303
Total Services
868
Medicare Billing
$39,698
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 23 | $2,300 | $565.29 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 91 | $14,560 | $5,943 | 40.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 74 | $7,220 | $3,009 | 41.7% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2022 | 21 | 69 | $2,760 | $212.32 | 7.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 45 | 173 | $25,440 | $12,615 | 49.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 35 | $3,150 | $1,747 | 55.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $4,225 | $1,637 | 38.7% |
| 96127 | Brief emotional or behavioral assessment | Office | 2021 | 39 | 112 | $4,480 | $387.03 | 8.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 45 | 167 | $23,380 | $10,708 | 45.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 20 | 20 | $6,500 | $2,575 | 39.6% |
| 96127 | Brief emotional or behavioral assessment | Office | 2020 | 37 | 91 | $3,640 | $299.62 | 8.2% |
About David Purselle, MD, MS
David Purselle, MD, MS is a Psychiatry healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356384135.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, David Purselle, MD, MS has received a total of $276,165 in payments from pharmaceutical and medical device companies, with $55,973 received in 2024. These payments were reported across 671 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($172,325).
As a Medicare-enrolled provider, Purselle has provided services to 303 Medicare beneficiaries, totaling 868 services with total Medicare billing of $39,698. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Atlanta, GA
- Active Since 06/13/2006
- Last Updated 03/02/2023
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1356384135
Products in Payments
- VRAYLAR (Drug) $95,642
- NUPLAZID (Drug) $47,964
- QELBREE (Drug) $37,998
- Qelbree (Drug) $24,012
- Auvelity (Drug) $21,502
- Brainsway Deep TMS (Device) $15,740
- SPRAVATO (Drug) $8,388
- QUVIVIQ (Drug) $6,595
- REXULTI (Drug) $5,584
- CAPLYTA (Drug) $909.98
- TRINTELLIX (Drug) $312.34
- BRINTELLIX (Drug) $282.17
- LATUDA (Drug) $271.44
- HETLIOZ (Drug) $268.44
- Trintellix (Drug) $213.19
- Dyanavel XR (Drug) $212.78
- ABILIFY MYCITE (Drug) $175.00
- Azstarys (Drug) $157.35
- Dayvigo (Drug) $154.76
- Xelstrym (Drug) $141.79
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Atlanta
Dr. Michael Burke, Md, MD
Psychiatry — Payments: $266,079
Psychiatry $266,079
Dr. Kerry Ressler, Md,Phd, MD,PHD
Psychiatry — Payments: $180,346
Psychiatry $180,346
Dr. Alyssa Rosen, M.d, M.D
Psychiatry — Payments: $128,521
Psychiatry $128,521
Boadie Dunlop, Md, MD
Psychiatry — Payments: $72,811
Psychiatry $72,811
Patricio Riva Posse, M.d, M.D
Psychiatry — Payments: $66,726
Psychiatry $66,726
Dr. Ray Horwitz, D.o, D.O
Psychiatry — Payments: $64,064
Psychiatry $64,064